Otsuka wins early FDA approval for a colorectal cancer combo drug

  • Otsuka,FDA,cancer,Lonsurf
  • fiercebiotech

Japanese drugmaker Otsuka won FDA approval for a two-drug therapy for colorectal cancer, planning to market the combination as a treatment for advanced forms of the disease.

The treatment, developed as TAS-102, combines the cancer-killing trifluridine with tipiracil, an agent designed to block enzymes that protect tumors from its partner chemical. The FDA cleared TAS-102 to treat refractory metastatic colorectal cancer, approving the therapy for patients whose tumors have spread despite first-line therapies.

Otsuka's drug met its goals in a Phase III study on 800 patients with previously treated metastatic colorectal cancer, beating placebo in extending progression-free survival, the FDA said.

The agency's approval comes almost three months ahead of schedule, underscoring the FDA's longstanding penchant for speedily signing off on new cancer treatments for the most dire patient populations.

The combo therapy is already on the market in Japan under the brand name Lonsurf. Otsuka submitted its treatment for European review in March, and the company has since signed a $130 million partnership with Servier that tasks the French drugmaker with marketing the drug on the continent.


This link:http://www.chemcd.com/news/18580.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

FDA Approves Exact Sciences' Cologuard; First and Only Stool DNA Noninvasive Colorectal Cancer Screening Test

2014/08/13 - FDA Approves Exact Sciences' Cologuard; First and Only Stool DNA Noninvasive Colorectal Cancer Screening Test First time in history a technology receives FDA approval and proposed national coverage by CMS on the same day

FDA Approves Pembrolizumab for Advanced Melanoma

2014/09/05 - Today the FDA approved Keytruda (pembrolizumab), a new treatment for advanced melanoma, the deadliest form of skin cancer. Melanoma patients have been waiting anxiously for this day, given the promising data that early studies have shown.

Prime Therapeutics urges FDA to keep current, consistent naming conventions for biologics, biosimilars

2014/09/09 - Prime Therapeutics, LLC (Prime) has submitted comments to the U.S. Food and Drug Administration (FDA) in support of two citizen petitions on the naming of biosimilar drugs. Biosimilars are medically equivalent versions of biologics, used to treat complex illnesses such as cancer.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

2015/10/20 - Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.

Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

2014/08/29 - Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study.

U.S. FDA Grants Priority Review Status to NDA for Anticancer Agent Lenvatinib

2014/10/17 - Eisai Co., Ltd.announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) submitted by its U.S. subsidiary Eisai Inc. for its novel in-house developed anticancer agent lenvatinib mesylate (lenvatinib) as a treatment for progressive radioiodine-refractory differentiated thyroid cancer and granted the NDA Priority Review status.